Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.59 |
| ▸ | CDK2 | P24941 | 17/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.59 |
| ▸ | CDK1 | P06493 | 10/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.58 |
| ▸ | CDK9 | P50750 | 7/20 | 0.56 |
| ▸ | CDK7 | P50613 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968043 | 0.95 | CDK4 (0.58) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968051 | 0.95 | CDK4 (0.58) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968038 | 0.89 | CDK4 (0.64) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968060 | 0.85 | CDK4 (0.61) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968026 | 0.85 | CDK4 (0.57) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968036 | 0.85 | CDK4 (0.62) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19967977 | 0.84 | CDK4 (0.60) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19967988 | 0.84 | CDK4 (0.58) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19968032 | 0.83 | CDK4 (0.63) | CDK4CDK2CDK6CDK1CCNB1 | |
| SCHEMBL19967982 | 0.82 | CDK4 (0.60) | CDK4CDK2CDK6CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018045956-A1 | BENZIMIDAZOLE COMPOUND KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2018-03-15 | — | — | WO | disclosed |